A Phase 2 interventional study of Hydroxyurea and Hydroxyurea in Sickle Cell Disease and Children, sponsored by Children's Hospital Medical Center, Cincinnati. Active, not recruiting at 4 sites in 4 countries. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one has the largest enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 55th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Theravia · Sites in France, French Guiana
Ages 9 mo–11 yrs
Vanderbilt University Medical Center · Sites in Nigeria
Ages 5–12
Brown University · Sites in Angola
Ages 6 mo–12 yrs
By country, each count listing its studies:
Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 3 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 12 · Phase 4 5
First in 1984; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 811 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 50 across the 57 interventional studies. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati: 7 open now, 11 under way, none of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 23rd registered.
Children's Hospital Medical Center, Cincinnati’s Anemia, Sickle Cell studies by the year they started, since 2005.
4 of the studies testing hydroxyurea in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, from their registry updates:
Among Children's Hospital Medical Center, Cincinnati’s 30 in Anemia, Sickle Cell:
This tab as a report to print or save as PDF → With an account.
REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.
REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs. In the REACH prospective trial, the Original Cohort will receive long-term treatment while for the New Cohort, treatment will continue at least 4 years using PK-guided dosing after an initial 3-month screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Pre-existing severe hematological toxicity (temporary exclusions)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The original REACH cohort continuing study treatment per the protocol schedule of evaluations.
Drug: Hydroxyurea
Newly enrolled REACH participants consent, 3 months screening, and treatment per the protocol schedule of evaluations
Drug: Hydroxyurea
Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
Efficacy of long-term Hydroxyurea treatment at MTD
The efficacy of hydroxyurea will be primarily assessed through fetal hemoglobin (HbF), comparing treatment with baseline values.
Time frame: Assessed every 6 ± 1 months up to 204 months
Reduction of malaria incidents while on hydroxyurea at MTD.
Clinical malaria infections to identify associations of risk or protection comparing treated and untreated incidents.
Time frame: Assessed every 4 ± 1 weeks, then every 3 ± 1months up to 204 months
Success of PK-guided dosing of hydroxyurea
Fetal Hemoglobin changes from hydroxyurea at MTD
Time frame: Assessed every 6 ± 1 months up to 204 months
Plan to share: Yes — Investigators whose proposed use of the data has been approved by a review committee identified for this purpose, will be provided individual participant data that underlie the results reported from this study, after de-identification and publication. The data can be obtained via email to Dr. Ware as the corresponding author.
Supporting information: Study protocol
Time frame: Nine months following publication ending 36 months following publication.
Access criteria: For individual participant data meta-analysis after approval of a proposal and with a signed data access agreement.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 47 months after the start.
Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 47 months is below that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxyurea
Children's Hospital Medical Center, Cincinnati →